Collection of Blood From Patients With Prostate Cancer
About This Trial
- This research study collects blood samples from patients to help scientists learn how genetics affect prostate cancer and why some cancers stop responding to standard hormone treatments.
- It is open to adults aged 18 and older who have been diagnosed with prostate cancer.
- If you participate, you will have blood drawn during your regular clinic visits so researchers can study your genetic material.
- This study does not test a new medication, but your samples will help doctors better understand the disease and improve future cancer care.
More Information
- Background: - It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. - Genes contain the hereditary information that is passed down from parents to children.
- Although everyone has the same set of genes, individuals can have different forms of the same gene. - Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.
- Objectives: -To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.
- Eligibility: -All participants participating in NCI prostate cancer protocols.
- Design: - Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic. - Blood samples are collected at the initial visit or at follow-up visits. - DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines. - Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Who Can Enroll
- Age Range: 18 years and older
- Gender: Male
- Who This Trial is For: This research study collects blood samples from patients to help scientists learn how genetics affect prostate cancer and why some cancers stop responding to standard hormone treatments.
Study Details
- Start Date: February 28, 2007
- Lead Sponsor: National Cancer Institute (NCI)
Full Eligibility Criteria
Inclusion Criteria
Individuals 18 years of age and older are eligible.
Individuals with a diagnosis of prostate cancer are eligible.
Exclusion Criteria
Children are not eligible.